BACKGROUND: Primary treatment of central neurocytomas is surgical resection. Gamma Knife surgery is considered a valuable therapeutic option in case of residual (after subtotal resection) or recurrent central neurocytomas. Here, we focused on the role of F-18 fluroethyltyrosine as a marker to document tumor progression after initial resection, in the context of an atypical central neurocytoma. We also describe MIB-1's role in evaluating therapeutic decision-making. CASE PRESENTATION: Two patients with central neurocytomas were treated by Gamma Knife surgery in our center. The first case (31-year-old Caucasian male) had atypical central neurocytoma. Four and a half years after surgical resection, magnetic resonance imaging and F-18 fluroethyltyrosine documented clear progression of residual central neurocytoma, further treated by Gamma Knife surgery (18 Gy at 50%, target volume 1.4 cc, and prescription isodose volume 1.8 cc). The initial post-Gamma Knife surgery clinical course was uneventful, with progressive volumetric reduction of residual tumor up to 4.5 years, when out-of-field recurrence was suspected and confirmed by local F-18 fluroethyltyrosine hyperactivity. Second single-fraction Gamma Knife surgery was performed (18 Gy at 50%, target volume 0.49 cc, prescription isodose volume 0.72 cc). The second (32-year-old Caucasian female) had previous subtotal resection and typical central neurocytoma. Seven years later, she had residual tumor progression. Single-fraction Gamma Knife surgery was performed (16 Gy at 50% isodose line, target volume 1.7 cc, and prescription isodose volume 2.5 cc). Last follow-up showed tumor volume reduction. Follow-up magnetic resonance imaging showed important volumetric reduction of both treated lesions. CONCLUSIONS: In atypical central neurocytomas, F-18 fluroethyltyrosine could be used as postoperative examination to detect small tumor remnants, follow-up evaluation following the Gamma Knife surgery or, in select cases, following surgical resection. The role of MIB-1 is important in therapeutic decision-making, as tumors with MIB-1 exceeding 2% are characterized by more aggressive clinical course. Single-fraction Gamma Knife surgery remains a valuable therapeutic option for postoperative residual atypical central neurocytomas and central neurocytoma recurrences.

1st Faculty of Medicine Charles University Prague Prague Czech Republic

Centre Hospitalier Universitaire Regional de Lille Lille France

Department of Clinical Neurosciences Neurosurgery Service and Gamma Knife Center Lausanne University Hospital Lausanne Switzerland

Department of Neurosurgery and Neurooncology Military University Hospital Prague Prague Czech Republic

Institute of Radiation Physics Lausanne Switzerland

Radiation Oncology Department Lausanne University Hospital Lausanne Switzerland

Service of Nuclear Medicine and Molecular Imaging Lausanne University Hospital Lausanne Switzerland

Signal Processing Laboratory Lausanne Switzerland

University of Lausanne Lausanne Switzerland

Zobrazit více v PubMed

Hassoun J, Gambarelli D, Grisoli F, Pellet W, Salamon G, Pellissier JF, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol. 1982;56(2):151–156. doi: 10.1007/BF00690587. PubMed DOI

Hassoun J, Soylemezoglu F, Gambarelli D, Figarella-Branger D, von Ammon K, Kleihues P. Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol. 1993;3(3):297–306. doi: 10.1111/j.1750-3639.1993.tb00756.x. PubMed DOI

Lee J, Chang SM, McDermott MW, Parsa AT. Intraventricular neurocytomas. Neurosurg Clin N Am. 2003;14(4):483–508. doi: 10.1016/S1042-3680(03)00064-0. PubMed DOI

Rades D, Fehlauer F, Schild SE. Treatment of atypical neurocytomas. Cancer. 2004;100(4):814–817. doi: 10.1002/cncr.20032. PubMed DOI

Rades D, Fehlauer F. Treatment options for central neurocytoma. Neurology. 2002;59(8):1268–1270. doi: 10.1212/WNL.59.8.1268. PubMed DOI

Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, et al. Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1145–1154. doi: 10.1016/j.ijrobp.2006.10.018. PubMed DOI

Monaco EA, 3rd, Niranjan A, Lunsford LD. The management of central neurocytoma: radiosurgery. Neurosurg Clin N Am. 2015;26(1):37–44. doi: 10.1016/j.nec.2014.09.008. PubMed DOI

Yamanaka K, Iwai Y, Shuto T, Kida Y, Sato M, Hayashi M, et al. Treatment results of Gamma Knife radiosurgery for central neurocytoma: report of a Japanese multi-institutional cooperative study. World Neurosurg. 2016;90:300–305. doi: 10.1016/j.wneu.2016.03.016. PubMed DOI

Nakamura A, Kano H, Niranjan A, Lunsford LD. Radiosurgery for central neurocytoma. Prog Neurol Surg. 2019;34:232–237. doi: 10.1159/000493069. PubMed DOI

Kim CY, Paek SH, Jeong SS, Chung HT, Han JH, Park CK, et al. Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment. Cancer. 2007;110(10):2276–2284. doi: 10.1002/cncr.23036. PubMed DOI

Genc A, Bozkurt SU, Karabagli P, Seker A, Bayri Y, Konya D, et al. Gamma knife radiosurgery for cranial neurocytomas. J Neurooncol. 2011;105(3):647–657. doi: 10.1007/s11060-011-0635-0. PubMed DOI

Karlsson B, Guo WY, Kejia T, Dinesh N, Pan DH, Jokura H, et al. Gamma Knife surgery for central neurocytomas. J Neurosurg. 2012;117(Suppl):96–101. doi: 10.3171/2012.6.GKS12214. PubMed DOI

Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E. Recurrent central neurocytomas. Cancer. 2005;104(1):135–142. doi: 10.1002/cncr.21109. PubMed DOI

Takao H, Nakagawa K, Ohtomo K. Central neurocytoma with craniospinal dissemination. J Neurooncol. 2003;61(3):255–259. doi: 10.1023/A:1022553110232. PubMed DOI

Soylemezoglu F, Scheithauer BW, Esteve J, Kleihues P. Atypical central neurocytoma. J Neuropathol Exp Neurol. 1997;56(5):551–556. doi: 10.1097/00005072-199705000-00011. PubMed DOI

Brat DJ, Scheithauer BW, Eberhart CG, Burger PC. Extraventricular neurocytomas: pathologic features and clinical outcome. Am J Surg Pathol. 2001;25(10):1252–1260. doi: 10.1097/00000478-200110000-00005. PubMed DOI

Ogawa Y, Sugawara T, Seki H, Sakuma T. Central neurocytomas with MIB-1 labeling index over 10% showing rapid tumor growth and dissemination. J Neurooncol. 2006;79(2):211–216. doi: 10.1007/s11060-006-9129-x. PubMed DOI

Rades D, Schild SE, Fehlauer F. Prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology. 2004;62(6):987–989. doi: 10.1212/01.WNL.0000115392.21898.E3. PubMed DOI

Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18(3):426–434. doi: 10.1093/neuonc/nov148. PubMed DOI PMC

Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010;20(10):2496–2502. doi: 10.1007/s00330-010-1819-2. PubMed DOI

Mineura K, Sasajima T, Itoh Y, Sasajima H, Kowada M, Tomura N, et al. Blood flow and metabolism of central neurocytoma: a positron emission tomography study. Cancer. 1995;76(7):1224–1232. doi: 10.1002/1097-0142(19951001)76:7<1224::AID-CNCR2820760720>3.0.CO;2-R. PubMed DOI

Ohtani T, Takahashi A, Honda F, Ishiuchi S, Kurihara H, Inoue T, et al. Central neurocytoma with unusually intense FDG uptake: case report. Ann Nucl Med. 2001;15(2):161–165. doi: 10.1007/BF02988610. PubMed DOI

Sakamoto R, Okada T, Kanagaki M, Yamamoto A, Fushimi Y, Kakigi T, et al. Estimation of proliferative potentiality of central neurocytoma: correlational analysis of minimum ADC and maximum SUV with MIB-1 labeling index. Acta Radiol. 2015;56(1):114–120. doi: 10.1177/0284185114521187. PubMed DOI

Mackenzie IR. Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome. Cancer. 1999;85(7):1606–1610. doi: 10.1002/(SICI)1097-0142(19990401)85:7<1606::AID-CNCR24>3.0.CO;2-B. PubMed DOI

Kaur G, Kane AJ, Sughrue ME, Oh M, Safaee M, Sun M, et al. MIB-1 labeling index predicts recurrence in intraventricular central neurocytomas. J Clin Neurosci. 2013;20(1):89–93. doi: 10.1016/j.jocn.2012.05.025. PubMed DOI PMC

Tuleasca C, Leroy HA, Regis J, Levivier M. Gamma Knife radiosurgery for cervical spine lesions: expanding the indications in the new era of Icon. Acta Neurochir. 2016;158(11):2235–2236. doi: 10.1007/s00701-016-2962-6. PubMed DOI

Schild SE, Scheithauer BW, Haddock MG, Schiff D, Burger PC, Wong WW, et al. Central neurocytomas. Cancer. 1997;79(4):790–795. doi: 10.1002/(SICI)1097-0142(19970215)79:4<790::AID-CNCR16>3.0.CO;2-V. PubMed DOI

Bertalanffy A, Roessler K, Dietrich W, Aichholzer M, Prayer D, Ertl A, et al. Gamma knife radiosurgery of recurrent central neurocytomas: a preliminary report. J Neurol Neurosurg Psychiatry. 2001;70(4):489–493. doi: 10.1136/jnnp.70.4.489. PubMed DOI PMC

Hung YC, Lee CC, Yang HC, Mohammed N, Kearns KN, Sun SB, et al. Stereotactic radiosurgery for central neurocytomas: an international multicenter retrospective cohort study. J Neurosurg. 2020 doi: 10.3171/2020.1.JNS191515. PubMed DOI

Pan DH, Lee CC. The management of incidental central neurocytoma. Neurosurg Clin N Am. 2015;26(1):57–66. doi: 10.1016/j.nec.2014.09.010. PubMed DOI